Adma Biologics Stock Price, News & Analysis

ADMA Biologics has implemented a 6-month stockholder rights plan to shield itself and its shareholders from unwanted takeover bids. Each shareholder will receive one right for every outstanding common stock share, effective from December 30, 2021. The plan will conclude on June 15, 2022. This strategy is part of a broader review of financial and strategic alternatives, without indicating any current takeover threat. The rights plan is designed to ensure that any acquisition attempts are evaluated thoroughly by ADMA's Board of Directors.

ADMA Biologics has secured European Patent No. 3375789 for treating and preventing S. pneumoniae infections using standardized hyperimmune globulins. This patent strengthens ADMA's existing U.S. patents, enhancing its position in developing hyperimmune therapies for vulnerable populations. CEO Adam Grossman highlighted the patent's potential to attract collaboration in addressing unmet medical needs. ADMA aims to leverage its proprietary technology to develop hyperimmune globulins for infectious diseases. The patent is part of ADMA's broader strategy to expand its intellectual property portfolio.

ADMA Biologics has announced the election of Cyndi Tolman, Senior Vice President of Plasma Services, to the PPTA Source Board for the 2022-2024 term. This appointment is seen as a recognition of her leadership in expanding the ADMA BioCenters collection network. President and CEO Adam Grossman expressed confidence in Tolman's experience to advocate for access to plasma-derived therapies. The PPTA works to ensure affordable therapies and support regulatory dialogue. ADMA operates FDA-licensed facilities for plasma collection and has three FDA-approved plasma-derived biologics in its portfolio.

ADMA Biologics has expanded its operational footprint with the opening of a new plasma collection center in Myrtle Beach, SC. This addition brings the total to six operational centers, with three more under construction, highlighting the company's strategy to enhance its plasma supply chain. By the end of 2023, ADMA aims to have ten licensed plasma centers, bolstering its revenue growth potential for its commercial Immune Globulin portfolio. The new center is equipped with advanced technology to improve donation efficiency and is expected to support the company's goal of self-sufficiency in plasma supply.

ADMA Biologics reported a strong third quarter of 2021, with revenues of $20.7 million, reflecting a 101% increase from the previous year. For the first time, the company achieved a positive gross profit of approximately $0.4 million, narrowing its net loss to $17.7 million. The company's balance sheet was strengthened by a public offering, raising $57.5 million in gross proceeds. Looking ahead, ADMA aims to reach profitability by the first quarter of 2024 and is expanding its plasma collection network.

ADMA Biologics will announce its Q3 2021 financial results on November 10, 2021, after U.S. markets close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide company updates. ADMA, focused on specialty plasma-derived biologics, has three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®, aimed at treating immunodeficient patients. The company manufactures these products at its FDA-licensed facility in Florida.

ADMA Biologics announced the closing of its underwritten public offering of 50 million shares at $1.00 per share, with an additional 7.5 million shares sold through the underwriters’ option, totaling $57.5 million in gross proceeds. The funds will support the commercial sales of FDA-approved products, expand plasma collection facilities, increase manufacturing capacity, and explore business development opportunities. The offering was conducted under a previously filed shelf registration statement.

ADMA Biologics (ADMA) presented a poster at the ISIRV-WHO Conference detailing ASCENIV™'s use in treating a COVID-19 patient with severe respiratory distress. The study involved a 70-year-old male with bronchiectasis whose condition improved after receiving ASCENIV™ alongside other treatments. Ultimately, the patient's respiratory function recovered, indicating potential benefits of ASCENIV™ for vulnerable populations battling severe respiratory diseases. Further research is required to validate these findings.

ADMA Biologics has priced a public offering of 50 million shares at $1.00 each, aiming to raise around $50 million before expenses. The offering is set to close on October 25, 2021, pending standard conditions. The company has extended a 30-day option for underwriters to purchase an additional 7.5 million shares. Proceeds will be used for enhancing commercial sales of FDA-approved products, expanding plasma collection facilities, increasing manufacturing capacity, exploring new business opportunities, and general corporate expenses.